By proceeding, you agree to our Terms of Use and Privacy Policy.
Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.
04-08 December 2022
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS Brand New Session Themes for 2022: How to Develop an Antibody-based Drug from Discovery to IND? Adaptive Immune Receptor Repertoire Data Processi
Event Ended
Hybrid
Paid
San Diego
16-20 January 2023
PepTalk connects protein science researchers from around the globe to share case studies, unpublished data, breakthroughs, and solutions that support and enhance biotherapeutics R&D. This year’s event will feature world-renowned speakers, cutting-edg
22-23 June 2023
Our 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientist
USA
Boston
07-08 August 2023
Great progress has been made in studying cancer immunology and the development of immunotherapies. The complexity of the immune system and the duplicity of cancer, plus the expense of treatments and variable patient responses, make for a perfect data
Cell therapies such as CAR Ts are now a proven treatment approach for hematological cancers, but challenges remain around CAR T’s ability to target solid tumors. Cambridge Healthtech Institute’s Tenth Annual Advances in CAR T Therapy conference bring
Bispecific antibodies are generating increased excitement for their potential to effectively target complex diseases through a dual-engagement approach. There are many new and powerful breakthroughs with bispecific antibodies relating to fine tuning
08-09 August 2023
Advances in harnessing the immune system for therapeutic development have resulted in a robust pipeline of immuno-oncology therapies and novel combinations. A successful program requires appropriate models and tools for preclinical evaluation and eff
Up until now, the cell therapy industry has been driven by the remarkable success of CAR T therapy. However, many believe the future of immunotherapy lies with other cell types such as NKs, Gamma Deltas, B Cells, TILs, and B cells, which offer many a
In recent years, Immunotherapy has been at the forefront of oncology research. However, this has not been without issues. Some of which include applications to solid tumors, regulating biodistribution, and serious side effects. During this conference
13-16 December 2023
The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Deg